Call(s) to Action: Please stay tuned for a report on two Pharmaceutical companies competing to use a cannabis-based compound to treat a specific condition in children. One of the companies is a bullish call, and the other bearish. Here are […]
Shares of EXETF continue to hit new highs fueled by analyst price target raise to $8.75(from $6.75) and recent announcement it has reached a resolution with the Office of the Inspector General regarding some previous activities by it U.S operations. […]
Summary Cannabidiol (“CBD”), a cannabis-based substance, is the focus of INSY and GWPH, two companies competing to develop CBD for the treatment of Dravet Syndrome, a form of childhood epilepsy. Contrary to what appears to be respected analysts’ expectations, INSY […]